Corbus Pharmaceuticals Holdings Inc

CRBPNASDAQ · USD
2.44USD-0.30 (-11.30%)
112

Corbus Pharmaceuticals Holdings Inc (CRBP) Historical Volatility

CRBP's 30 day historical volatility is 115.95%, in the 87th percentile of readings over the past year. This is a high percentile, meaning Corbus Pharmaceuticals Holdings Inc shares have swung far more than usual. CRBP's 30 day implied volatility sits at 311.47%, with an IV Rank of 95.24%, leaving IV 195.52 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 18, 2026.

Read more

Tracking CRBP historical volatility helps you see how much Corbus Pharmaceuticals Holdings Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, CRBP's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor CRBP 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. CRBP's 30 day historical volatility, or CRBP HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing CRBP's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.

Historical Volatility

HV Percentile
87thHV Percentile
High

Historical movement is elevated versus the past year. The stock has been unusually active.

Historical Volatility (30d)115.95%

HV Percentile87th

Implied Volatility (30d)311.47%

IV Rank95.24%

IV Minus HV+195.52%

As of Nov 18, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 18, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 18, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →